智通财经网·2026-01-07 02:50Group 1 - The CRO concept stocks have collectively risen, with notable increases in share prices for companies such as Kintor Pharmaceutical (6.27% increase), Tigermed (5.48% increase), and WuXi AppTec (3.12% increase) [1] - Zhongtai Securities believes that the CRO and CDMO industries are experiencing a resonance in both domestic and foreign demand, with a gradual clearing of supply [1] - The demand side is expected to gradually recover due to multiple factors, including the onset of overseas interest rate cuts in Q4 2024, improved pessimistic expectations from geopolitical negotiations in Q2 2025, and the rollout of major domestic innovative drug business development [1] Group 2 - Industrial growth in the CRO sector is being driven by the overseas expansion of innovative drug business development and a stabilization in financing, leading to a double-digit growth in new orders [2] - There is a rising trend in pricing for experimental monkeys, safety evaluation quotes, and clinical project prices since Q4, indicating strong customer demand [2] - The global position of Chinese CDMO in the supply chain is deemed irreplaceable, and the anticipated interest rate cuts by the Federal Reserve are expected to boost early-stage global research and development demand [2]